Regeneron Fianlimab-Libtayo Trial Securities Class Action
Analysis based on 240 articles · First reported Jul 16, 2026 · Last updated Sep 11, 2026
The litigation reinforces negative sentiment around Regeneron by keeping the failed Fianlimab-Libtayo melanoma trial and the alleged disclosure failures in the headlines, sustaining uncertainty over potential damages and management credibility. Broader market impact is limited and largely idiosyncratic to Regeneron and the biotech sector, though the case adds to the ongoing wave of securities class actions that raise governance and disclosure-risk concerns for large-cap pharmaceutical issuers.
Regeneron Pharmaceuticals faces a consolidated securities fraud class action in the U.S. District Court for the Southern District of New York (Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026) filed on behalf of investors who purchased or otherwise acquired Regeneron common stock between August 1, 2025 and May 15, 2026. The complaint alleges that Regeneron and certain of its top executives made materially false and misleading statements and failed to disclose that the preliminary statistical assumptions underlying its Phase III Fianlimab-Libtayo study were fundamentally flawed, that the active treatment arm was not achieving meaningful clinical differentiation over standard therapies, and that the trial was unlikely to reach statistical significance on its primary endpoint even absent overperformance of the control arm. According to the complaint, on April 29, 2026, during Regeneron's first quarter earnings call, the company disclosed that the study protocol had been altered to expand the number of patients eligible for progression-free survival analysis; Regeneron stock fell $45.41, or about 6.2%, to close at $686.36 that day. On May 15, 2026, Regeneron reportedly announced that the Phase 3 trial of Fianlimab did not reach statistical significance for the primary endpoint of improvement in progression-free survival; the stock fell $68.57, or about 9.8%, to close at $629.68 on May 18, 2026. The decline was described as an approximately $11 billion market capitalization wipeout. Multiple national shareholder-rights firms, including Bronstein, Gewirtz & Grossman, LLC, Hagens Berman, Pomerantz LLP, Robbins Geller Rudman & Dowd LLP, Faruqi & Faruqi, The Gross Law Firm, The Schall Law Firm, and DJS Law Group, have issued notices urging investors to seek appointment as lead plaintiff before the September 14, 2026 deadline. The class has not yet been certified.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard